Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study.
Under the auspices of the Southwest Oncology Group, Wayne State University tested a schedule using bleomycin and mitomycin C that was previously reported to give a response rate of 88%. In our patients the same regimen produced similar toxic effects but a far different response rate of 15.8% (one complete remission and two partial remissions). The only discernible difference in the two patient groups was the amount of radiation given prior to chemotherapy.
D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D001761:Bleomycin